Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Usmani on the Risk-Benefit Profile of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 15th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

April 12th 2024

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

April 11th 2024

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Usmani on the Optimal Role for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 10th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

April 8th 2024

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

Dr Dima on Real-World Responses With Teclistamab in R/R Multiple Myeloma

April 5th 2024

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

April 5th 2024

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

April 5th 2024

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

April 4th 2024

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Dr Baz on AE Management Discussions in Multiple Myeloma

March 29th 2024

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Dr Parrondo on the Use of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

March 28th 2024

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Dr Mikhael on Unmet Needs to Be Addressed in Multiple Myeloma

March 27th 2024

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma

March 25th 2024

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Ide-Cel Receives EU Approval for Triple Class–Exposed R/R Multiple Myeloma

March 21st 2024

The European Commission has approved idecabtagene vicleucel for triple-class–exposed relapsed/refractory multiple myeloma.

Dr Richter on Ongoing Research With Bispecific Antibodies in R/R Multiple Myeloma

March 19th 2024

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

FDA ODAC Committee Votes in Favor of Benefit-Risk Profile of Ide-Cel in Early R/R Myeloma

March 15th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of idecabtagene vicleucel for patients with early relapsed/refractory myeloma.

FDA ODAC Committee Votes Unanimously in Favor of Benefit-Risk Profile of Cilta-Cel in Early R/R Myeloma

March 15th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of ciltacabtagene autoleucel for patients with early relapsed/refractory myeloma.

FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma

March 14th 2024

P-BCMA-ALLO1 has been granted orphan drug designation by the FDA for the treatment of patients with relapsed/refractory multiple myeloma.